STOCK TITAN

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ovid Therapeutics (NASDAQ: OVID) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 9:10 a.m. ET. Investors can access the live audio webcast on the Company’s website, with an archived replay available afterward. Ovid focuses on developing therapies for rare neurological diseases using its BoldMedicine® approach. Its pipeline includes promising candidates addressing disorders such as Tuberous Sclerosis Complex and Angelman syndrome, with significant collaborations and research underway.

Positive
  • None.
Negative
  • None.

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.

A live audio webcast of the virtual fireside chat can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. We believe these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years and today represents a substantial opportunity medically and commercially. Based on recent scientific advances in genetics and the biological pathways of the brain, we aim to identify, discover and acquire novel compounds for the treatment of rare neurological disorders. We have built a deep knowledge of such disorders, how to treat them and how to develop the clinically meaningful endpoints required for development of a compound in these disorders. We continue to execute on our strategy to build this pipeline by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions. Ovid’s emerging pipeline programs include OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a genetic therapy approach for KIF1A associated neurological disorder; and other non-disclosed research targets. Additionally, Ovid maintains a significant financial interest in a program directed to the exploitation of soticlestat, for which Takeda is responsible for the global development and commercialization, if soticlestat is successfully developed and commercialized. Two phase 3 trials for soticlestat in Dravet syndrome and Lennox-Gastaut syndrome are expected to begin in mid-2021.
For more information on Ovid, please visit www.ovidrx.com.

Contacts

Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
irpr@ovidrx.com

OR

Investors:
Argot Partners
Dawn Schottlandt
212-600-1902
ovid@argotpartners.com

Media:
Dan Budwick
1AB
dan@1abmedia.com


FAQ

What will Ovid Therapeutics discuss at the 2021 RBC Capital Markets Global Healthcare Conference?

Ovid Therapeutics will discuss their pipeline and approach to developing therapies for rare neurological diseases.

When is the Ovid Therapeutics virtual fireside chat scheduled?

The virtual fireside chat is scheduled for May 19, 2021, at 9:10 a.m. ET.

How can I access the Ovid Therapeutics webcast?

The live audio webcast can be accessed through the Events & Presentations section of Ovid's website.

What are the key programs in Ovid Therapeutics' pipeline?

Ovid's pipeline includes OV329 for Tuberous Sclerosis Complex, OV882 for Angelman syndrome, and OV815 for KIF1A associated neurological disorder.

What is Ovid Therapeutics' focus in drug development?

Ovid Therapeutics focuses on developing medicines specifically for rare neurological disorders.

Ovid Therapeutics Inc.

NASDAQ:OVID

OVID Rankings

OVID Latest News

OVID Stock Data

73.85M
59.72M
15.9%
56.45%
1.07%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK